UCSF

Tagged: School of Pharmacy

QBI fellowship fosters curiosity and perseverance for women scientists

Jacqueline Kyosiimire-Lugemwa, the first recipient of QBI’s Scholarship for Women from Developing Nations in Biosciences, spent a year at UCSF in which her perseverance in the sciences was tested. She recently returned to her home country of Uganda more ready than ever to tackle big questions about HIV.

Federal shutdown cancels CERSI conference aimed at health care cooperation

Federal shutdown cancels conference aimed at health care cooperation
Fri Jan 4, 2019

CRISPR-based obesity treatment shows promise for other diseases

A recent study by Nadav Ahituv, PhD, showed that obesity caused by a gene mutation could be treated in animal models.

COSA Winter Auction

Wed Feb 20, 2019 - 4:30 pm to 8:00 pm

Fraser appointed to Bowes Biomedical Investigator Program

Fraser developed several new tools for creating maps of macromolecules, a critical first step for finding new drugs.

Keiser receives $2.5 million to apply machine learning towards new therapies for Alzheimer’s, Parkinson’s

Michael Keiser, PhD, received a Ben Barres Early Career Acceleration Award from the Chan Zuckerberg Initiative, which will fund his research into novel therapies for neurodegeneration.

Combination drug therapy overcomes drug-resistant lung cancer in the lab

Many types of lung cancer thwart even the most targeted of therapies due to drug resistance, but a group of UCSF scientists led by Sourav Bandyopadhyay, PhD, have now shown that adding a second drug into treatment regimens can overcome this resistance in lab-grown, lung cancer cell lines.

Paul R. Ortiz de Montellano elected a fellow of the Royal Society of Chemistry

Ortiz de Montellano gained renown for his work with cytochrome P450 enzymes, which help the liver metabolize drugs and other chemicals, and regulate hormone levels.

QBI scientists decipher how Ebola, dengue, and Zika infect human cells

In a pair of recent studies, scientists at the Quantitative Biosciences Institute uncovered how Ebola, dengue, and Zika hijack human proteins to infect human cells, findings that point to new approaches for treating these diseases.

Research points to individualized treatments for curing TB

Tuberculosis is usually treated with a six month regimen of daily antibiotics, but millions of patients do not recover from the disease during treatment. Rada Savic’s team showed that adjusting the duration of this regimen based on disease severity could lead to better outcomes.

Pages